Core Insights - Rippling, an HR software startup, raised $450 million in Series G funding, achieving a valuation of $16.8 billion, focusing on global revenue growth over immediate profitability [1][4][5] Funding and Valuation - The funding round included participation from notable investors such as Y Combinator, Elad Gil, Sands Capital, GIC, and Goldman Sachs Growth [2] - The new valuation of $16.8 billion marks an increase from the previous valuation of $13.5 billion in early 2024 [4] Employee Equity and IPO Plans - Rippling plans to repurchase up to $200 million of equity from current and former employees through a tender offer, which may become an annual event [2][3] - The CEO stated that the company does not have immediate plans for an IPO, emphasizing the need for profitability before considering going public [4][6] Business Performance and Strategy - Rippling has surpassed $100 million in annual recurring revenue and serves over 20,000 customers with a suite of more than 20 products [5] - The company is prioritizing growth over profitability, indicating a strategic choice to expand rapidly rather than slow down for immediate profit [6] Legal Challenges - Rippling is involved in ongoing legal disputes with competitor Deel, including allegations of corporate espionage, which have raised questions about competitive practices in the tech industry [7][8]

Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTC: CWBHF) Q4 2025 Earnings: Revenue Beats, Wider Net Loss, Major BAT Strategic TransactionRevenue Beat: Reported Q4 revenue of $13.3 million, exceeding the estimated ~$12.3 million and up 4.7% year-over-year.EPS Miss: GAAP EPS of -$0.07 (basic and diluted), missing the consensus estimate of approximately -$0.03 to -$0.04.Strategic BAT Transaction: Agreement for conversion of C$75.3 million convertible debenture (plus accrued interest) into common shares and a ne ...

J.Jill, Inc. (NYSE:JILL) Q4 2025 Earnings: Revenue Misses Estimates, EPS Misses, Dividend RaisedRevenue Below Estimates: J.Jill reported $138.41 million in net sales for the fourth quarter, falling short of the consensus estimate of approximately $142.33 million.Profitability Challenges: The company posted a GAAP EPS loss and a net loss of $3.5 million. Adjusted EPS was around a $0.02 loss. Operating performance was pressured by tariffs, promotions, and a tough retail environment.Dividend Increase: The quar ...

EPS Misses Estimates: BIO-key International, Inc. ((NASDAQ:BKYI)) reported an EPS of -$0.19, below the estimated EPS of -$0.07, indicating a larger-than-expected loss per share. Revenue Growth and Cash Position: Quarterly revenue was $1.24 million (vs. estimated $2.2 million), but full-year 2025 revenue reached $6.1 million. Cash position improved to $2.7 million at the end of 2025, up from $400,000 in 2024. Positive Outlook for 2026: Preliminary Q1 2026 revenue is $2.2 million, a 37% increase year-over-ye ...

The company says it will take the money that would have gone toward Beck's future wages and bonuses and put it toward R&D projects. ...

T1 Energy Inc. (NYSE: TE) Reports Q4 2025 Results Amid Ongoing Progress on G2_Austin Solar Cell ProjectEarnings Miss on Bottom Line: T1 Energy reported a GAAP EPS of -$0.87 (including discontinued operations) versus analyst expectations around break-even to slightly positive. Revenue came in at $358.6 million, slightly below the consensus estimate of $368.2 million.Key Financials: The company posted a net loss of $190 million in Q4 2025. From continuing operations, the loss was narrower at approximately $15 ...

HGV Investor Overview M A R C H 2 0 2 6 Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements convey management's expectations as to the future of HGV, and are based on management's beliefs, expectations, assumptions and such plans, estimates, projections and other information available to management at the time ...

复星国际 其中，核心子公司复星医药（600196），2025年归母净利润33.71亿元，同比增长21.69%。复星医药旗 下的生物医药创新平台复宏汉霖，2025年也实现营收人民币66.67亿元，净利润人民币8.27亿元，连续三 年实现营收、利润双增长。 再看复星最重要的海外子公司复星葡萄牙保险，2025年收入和净利润实现强劲增长，实现归母净利润 2.01亿欧元，同比增长15.8%，成为复星稳定的利润来源。复星的全球化生态对复星葡萄牙保险助力甚 多，公司业务已从葡萄牙本土覆盖到欧洲、拉美、非洲等海外区域。2025年葡萄牙保险首次被标普授予 A级评级，资产质量与抗风险能力获国际认可。 在国内，复星两家保险公司也表现不俗。复星保德信人寿全年规模保费达132.8亿元，同比增长41.6%， 实现净利润6.5亿元，同比大幅增长超492%；复星联合健康保险2025年的收入达到78.4亿元，同比增长 50.1%，全年实现净利润1.39亿元，连续五年盈利。 分时图 日K线 周K线 月K线 4.14 0.10 2.48% 4.46% 2.97% 1.49% 0.00% 1.49% 2.97% 4.46% 3.86 3.92 3. ...

复星国际 于授出日期本公司已根据于2023年3月16日采纳的股份奖励计划，向身为本集团董事及雇员的76名2023 奖励计划的合资格参与者授出2977.7万股奖励股份。2026年奖励下授予之奖励股份将通过以下方式满 足：(i)在2023奖励计划的计划授权限额内发行2659.57万股新股份及(ii)使用于归属前失效之318.13万股 奖励股份。 分时图 日K线 周K线 月K线 4.14 0.10 2.48% 4.46% 2.97% 1.49% 0.00% 1.49% 2.97% 4.46% 3.86 3.92 3.98 4.04 4.10 4.16 4.22 09:30 10:30 12:00/13:00 14:00 16:10 0 71万 142万 213万 复星国际(00656)发布公告，于2026年3月31日，公司已根据于2023年3月16日采纳的购股权计划，向身 为本集团董事及雇员的160名2023购股权计划的合资格参与者授出3.63亿份购股权，以认购合共3.63亿股 本公司股份，惟须待购股权承授人接纳后方可作实。 ...

在剥离非核心资产、计提减值的同时，复星国际的核心业务板块仍展现出较强的韧性。 "过去复星特别勇敢，做了很多尝试，有成功的，也有失败的，总体付了不少学费。"郭广昌在信中表 示，"回过头看，我们过往布局的一些项目，确实在当期的市场形势和我们投资之初存在价值的偏 差。"他强调，此次计提不会影响公司日常经营、现金流及业务运转。 财报指出，减值主要源于附属公司豫园股份因行业周期下行，对旗下部分商业房地产项目和商誉计提了 大额资产减值准备，导致豫园股份自身由盈转亏，净亏损49.0亿元。同时，集团也对百合佳缘、St Hubert等资产的商誉进行了减值处理。 在郭广昌看来，这是一次"晴天修屋顶"的战略性选择。"正是有扎实的家底，以及合作伙伴一如既往的 支持，才让我们有底气和决心，在此刻放下包袱，去追求未来可预见、可持续的增长。"通过这次资产 减值出清，复星希望将资源和精力更集中地投向高增长的核心赛道，实现"更轻盈、健康、可持续"的发 展。 全球化收入海外占比过半 复星国际 大额减值拖累巨亏234亿 财报数据显示，此次大额减值主要影响集中在快乐和富足板块。其中，快乐板块（含豫园股份 （600655）、复星旅文等）录得归属于母公 ...